Atea and Roche's COVID-19 antiviral flunks phase 2, prompting switch that will delay pivotal data

Retrieved on: 2021-10-19 19:56:10

Tags for this article:

Click the tags to see associated articles and topics

Atea and Roche's COVID-19 antiviral flunks phase 2, prompting switch that will delay pivotal data. View article details on hiswai:

Excerpt

Atea Pharmaceuticals and Roche have suffered a big blow to their bid to bring an oral antiviral for COVID-19 to market. A phase 2 trial of the ...

Article found on: www.fiercebiotech.com